-
1 Comment
Jinyu Bio-technology Co., Ltd is currently in a long term downtrend where the price is trading 17.0% below its 200 day moving average.
From a valuation standpoint, the stock is 60.9% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 15.5.
Jinyu Bio-technology Co., Ltd's total revenue rose by 43.6% to $483M since the same quarter in the previous year.
Its net income has increased by 44.4% to $113M since the same quarter in the previous year.
Finally, its free cash flow grew by 1691.8% to $218M since the same quarter in the previous year.
Based on the above factors, Jinyu Bio-technology Co., Ltd gets an overall score of 3/5.
| Industry | Biotechnology |
|---|---|
| Exchange | SHG |
| CurrencyCode | CNY |
| ISIN | CNE000000Y37 |
| Sector | Healthcare |
| Dividend Yield | 0.3% |
|---|---|
| Beta | 0.65 |
| Market Cap | 13B |
| PE Ratio | 127.33 |
| Target Price | 7.18 |
Jinyu Bio-technology Co., Ltd. engages in the research and development, production, and sale of veterinary biological products in China and internationally. The company's products focus on preventing porcine mycoplasmal pneumonia, pseudorabies, highly pathogenic avian influenza, brucellosis, and other Class I, II, and III animal diseases. It also provides pig vaccines, swine foot-and-mouth disease type O and A bivalent inactivated, porcine circovirus type 2 baculovirus vector inactivated, porcine reproductive and respiratory syndrome chimeric virus live and inactivated, and swine fever live, transmissible gastroenteritis in pigs, swine live influenza bivalent, bovine viral diarrhea/mucosal disease, infectious rhinitis two-dose inactivated, brucella gene-deleted live, brucellosis live, inactivated emphysema and gangrene, ruminant disease live, newcastle disease, infectious bursal disease trivalent inactivated, recombinant avian influenza virus trivalent inactivated, infectious bronchitis symptoms, egg drop syndrome type 4 quadrivalent inactivated infectious bronchitis, canine distemper and parvovirus bivalent live, feline panleukopenia calicivirus disease trivalent inactivated trivalent, and inactivated rabies vaccines. Further, the company manufactures and sells biological pharmaceutical preparations, and chemical reagents and auxiliaries; develops biotechnology; transfer and consulting services; advanced medical equipment and instruments; import and export of goods and technology; and provision of property management services. Additionally, it is involved in real estate activities; biochemical products; planting; hotel management services; internet information service finance; biotechnology promotion services; owner-owned house for rent; mechanical equipment processing; investment management; management, meal, technical, and medical services; and trading activities. Jinyu Bio-technology Co., Ltd. was founded in 1992 and is based in Hohhot, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 600201.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
